Skip to content
Peptide research

Prostamax

Category
Bioregulators
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A synthetic tetrapeptide marketed for prostate health, promoted to calm chronic inflammation and support tissue repair as the prostate ages. The case is speculative, resting on mechanistic and animal-model reasoning rather than controlled human trials, with no established human safety profile. A theoretical concern about promoting growth in existing prostate malignancy is unresolved. Products sold online are unregulated, and it is not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(6)

  • Reduction of chronic prostate inflammation

    Speculative

    A rat prostatitis study reports reduced inflammation; human benefit remains unestablished.

  • Prevention of sclerotic and atrophic processes in prostate tissue

    Speculative

    A rat prostatitis study measured sclerosis and atrophy; human prevention remains unestablished.

  • Epigenetic reactivation of age-silenced genes via chromatin decondensation

    Low

    Human lymphocyte study found chromatin decondensation signals, but unreplicated and not clinical.

Evidence limits

Evidence Level
Preclinical

The peer-reviewed evidence described here is mainly preclinical and ex vivo. Patent RU2177802C1 additionally reports human KEDP treatment series and animal toxicology; these disclosures are not independently validated clinical trials. The cited rat and cell studies do not establish human efficacy or safety. No controlled peer-reviewed human trial was identified. The most substantive evidence comes from the Borovskaya et al. 2013 study in 60 rats, which demonstrated anti-inflammatory, anti-fibrotic, and anti-atrophic effects superior to established comparator agents. Ex vivo studies in human lymphocytes from elderly subjects (Khavinson et al. 2004, Dzhokhadze et al. 2012) show measurable epigenetic effects on chromatin structure. The organotypic tissue culture study (Zakutskii et al. 2006) confirms tissue-specific activity on prostate explants. The major limitations are origin in a single research group, small sample sizes, no peer-reviewed pharmacokinetic or toxicology data, and no independent replication by non-affiliated laboratories.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Very limited human evidence — safety and efficacy remain unestablished

    High
  • Theoretical risk of tumor promotion in active prostate malignancy

    Theoretical
  • Unregulated product quality (research-grade sources)

    High
  • Limited safety data and lack of independent validation

    High
  • Allergic reaction or peptide hypersensitivity

    Low
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.